Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma

STOCKHOLM, 9 November, 2018 -- Promore Pharma AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2019, which will be held on Tuesday 21 May 2019. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the Chairman of the Board and representatives for the three largest shareholders in the company.

The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of the Chairman of the Board and members appointed by the three largest shareholders in the company based on ownership of the Company as per the end of September 2018.

Accordingly, the following committee members have been appointed:

  • Göran Pettersson, Chairman of the Board
  • David Sundin, representing Midroc New Technology
  • Graham Fagg, representing Rosetta Capital
  • Per Lönn, representing PharmaResearch Products

The Nomination Committee’s proposals will be presented in the Notice to the AGM 2019 and on the company web site, www.promorepharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via email to info@promorepharma.com.

For additional information, please contact

Jonas Ekblom, President and CEO

Tel: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Jenni Björnulfson, CFO

Tel: [+46] 708 55 38 05

E-mail: jenni.bjornulfson@promorepharma.com

Promore Pharma in brief:

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 has initiated a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North.

Subscribe

Documents & Links